• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利尿剂作为原发性高血压二线治疗的降压疗效

Blood pressure lowering efficacy of diuretics as second-line therapy for primary hypertension.

作者信息

Chen Jenny Mh, Heran Balraj S, Wright James M

机构信息

Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Vancouver, BC, Canada, V6T 1Z3.

出版信息

Cochrane Database Syst Rev. 2009 Oct 7(4):CD007187. doi: 10.1002/14651858.CD007187.pub2.

DOI:10.1002/14651858.CD007187.pub2
PMID:19821398
Abstract

BACKGROUND

Diuretics are widely prescribed for hypertension not only as a first-line drug but also as a second-line drug. Therefore, it is essential to determine the effects of diuretics on blood pressure (BP), heart rate and withdrawals due to adverse effects (WDAEs) when given as a second-line drug.

OBJECTIVES

To quantify the additional reduction in systolic blood pressure (SBP) and diastolic blood pressure (DBP) of diuretic therapy as a second-line drug in patients with primary hypertension

SEARCH STRATEGY

CENTRAL (The Cochrane Library 2008, Issue 2), MEDLINE (1966-July 2008), EMBASE (1988-July 2008) and bibliographic citations of articles and reviews were searched.

SELECTION CRITERIA

Double-blind, randomized, controlled trials evaluating the BP lowering efficacy of a diuretic in combination therapy with another class of anti-hypertensive drugs compared with the respective monotherapy (without a diuretic) for a duration of 3 to 12 weeks in patients with primary hypertension.

DATA COLLECTION AND ANALYSIS

Two review authors independently extracted the data and assessed trial quality.

MAIN RESULTS

Fifty-three double-blind RCTs evaluating a thiazide in 15129 hypertensive patients (baseline BP of 156/101 mmHg) were included. Hydrochlorothiazide was the thiazide used in 49/53 (92%) of the included studies. The additional BP reduction caused by the thiazide as a second drug was estimated by comparing the difference in BP reduction between the combination and monotherapy groups. Thiazides as a second-line drug reduced BP by 6/3 and 8/4 mmHg at doses of 1 and 2 times the manufacturer's recommended starting dose respectively. The BP lowering effect was dose related. The effect was similar to that obtained when thiazides are used as a single agent. Only 3 double-blind RCTs evaluating loop diuretics were identified. These RCTs showed a BP lowering effect of a starting dose of about 6/3 mmHg.

AUTHORS' CONCLUSIONS: Thiazides when given as a second-line drug have a dose related effect to lower blood pressure that is similar to when they are added as a first-line drug. This means that the BP lowering effect of thiazides is additive. Loop diuretics appear to have a similar blood pressure lowering effect as thiazides at 1 times the recommended starting dose. Because of the short duration of the trials and lack of reporting of adverse events, this review does not provide a good estimate of the incidence of adverse effects of diuretics given as a second-line drug.

摘要

背景

利尿剂不仅作为一线药物,也作为二线药物被广泛用于治疗高血压。因此,确定利尿剂作为二线药物使用时对血压(BP)、心率和因不良反应导致的停药(WDAEs)的影响至关重要。

目的

量化利尿剂作为二线药物治疗原发性高血压患者时收缩压(SBP)和舒张压(DBP)的额外降低幅度。

检索策略

检索了CENTRAL(《考克兰系统评价数据库》2008年第2期)、MEDLINE(1966年 - 2008年7月)、EMBASE(1988年 - 2008年7月)以及文章和综述的参考文献。

选择标准

双盲、随机、对照试验,评估利尿剂与另一类抗高血压药物联合治疗时的降压效果,并与原发性高血压患者中相应的单药治疗(无利尿剂)进行比较,疗程为3至12周。

数据收集与分析

两位综述作者独立提取数据并评估试验质量。

主要结果

纳入了53项双盲随机对照试验,共15129例高血压患者(基线血压为156/101 mmHg),评估噻嗪类药物的效果。49/53(92%)的纳入研究使用的噻嗪类药物为氢氯噻嗪。通过比较联合治疗组和单药治疗组血压降低的差异,估算噻嗪类药物作为二线药物导致的额外血压降低幅度。噻嗪类药物作为二线药物,在剂量分别为制造商推荐起始剂量的1倍和2倍时,收缩压分别降低6/3 mmHg和8/4 mmHg,舒张压降低效果与剂量相关,且与噻嗪类药物作为单一药物时的效果相似。仅识别出3项评估袢利尿剂的双盲随机对照试验,这些试验显示起始剂量的降压效果约为6/3 mmHg。

作者结论

噻嗪类药物作为二线药物使用时,其降压效果与剂量相关,且与作为一线药物添加时相似,这意味着噻嗪类药物的降压效果具有相加性。袢利尿剂在推荐起始剂量1倍时似乎具有与噻嗪类药物相似的降压效果。由于试验持续时间较短且未报告不良事件,本综述无法很好地估计利尿剂作为二线药物使用时不良反应的发生率。

相似文献

1
Blood pressure lowering efficacy of diuretics as second-line therapy for primary hypertension.利尿剂作为原发性高血压二线治疗的降压疗效
Cochrane Database Syst Rev. 2009 Oct 7(4):CD007187. doi: 10.1002/14651858.CD007187.pub2.
2
Blood pressure lowering efficacy of beta-blockers as second-line therapy for primary hypertension.β受体阻滞剂作为原发性高血压二线治疗的降压疗效。
Cochrane Database Syst Rev. 2010 Jan 20(1):CD007185. doi: 10.1002/14651858.CD007185.pub2.
3
Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension.噻嗪类利尿剂单药治疗原发性高血压的降压疗效。
Cochrane Database Syst Rev. 2014 May 29;2014(5):CD003824. doi: 10.1002/14651858.CD003824.pub2.
4
Blood pressure lowering efficacy of potassium-sparing diuretics (that block the epithelial sodium channel) for primary hypertension.保钾利尿剂(阻断上皮钠通道)对原发性高血压的降压疗效。
Cochrane Database Syst Rev. 2012 Nov 14;11(11):CD008167. doi: 10.1002/14651858.CD008167.pub3.
5
Blood pressure lowering efficacy of potassium-sparing diuretics (that block the epithelial sodium channel) for primary hypertension.保钾利尿剂(阻断上皮钠通道)对原发性高血压的降压疗效。
Cochrane Database Syst Rev. 2010 Jan 20(1):CD008167. doi: 10.1002/14651858.CD008167.pub2.
6
Pharmacological interventions for hypertension in children.儿童高血压的药物治疗干预措施。
Cochrane Database Syst Rev. 2014 Feb 1;2014(2):CD008117. doi: 10.1002/14651858.CD008117.pub2.
7
Blood pressure lowering efficacy of partial agonist beta blocker monotherapy for primary hypertension.部分激动剂β受体阻滞剂单药治疗原发性高血压的降压疗效
Cochrane Database Syst Rev. 2014 Nov 27;2014(11):CD007450. doi: 10.1002/14651858.CD007450.pub2.
8
Blood pressure lowering efficacy of loop diuretics for primary hypertension.袢利尿剂对原发性高血压的降压疗效
Cochrane Database Syst Rev. 2012 Aug 15(8):CD003825. doi: 10.1002/14651858.CD003825.pub3.
9
Blood pressure lowering efficacy of loop diuretics for primary hypertension.袢利尿剂对原发性高血压的降压疗效。
Cochrane Database Syst Rev. 2009 Oct 7(4):CD003825. doi: 10.1002/14651858.CD003825.pub2.
10
Pharmacological interventions for hypertension in children.儿童高血压的药物干预措施。
Evid Based Child Health. 2014 Sep;9(3):498-580. doi: 10.1002/ebch.1974.

引用本文的文献

1
Benefit of treatment based on indapamide mostly combined with perindopril on mortality and cardiovascular outcomes: a pooled analysis of four trials.基于吲达帕胺联合培哚普利治疗对死亡率和心血管结局的获益:四项试验的汇总分析。
J Hypertens. 2023 Mar 1;41(3):508-515. doi: 10.1097/HJH.0000000000003368. Epub 2023 Jan 19.
2
Blood pressure-lowering efficacy of loop diuretics for primary hypertension.襻利尿剂对原发性高血压的降压疗效
Cochrane Database Syst Rev. 2015 May 22;2015(5):CD003825. doi: 10.1002/14651858.CD003825.pub4.
3
Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension.

本文引用的文献

1
Blood pressure lowering efficacy of beta-blockers as second-line therapy for primary hypertension.β受体阻滞剂作为原发性高血压二线治疗的降压疗效。
Cochrane Database Syst Rev. 2010 Jan 20(1):CD007185. doi: 10.1002/14651858.CD007185.pub2.
2
First-line drugs for hypertension.高血压一线用药。
Cochrane Database Syst Rev. 2009 Jul 8(3):CD001841. doi: 10.1002/14651858.CD001841.pub2.
3
Factors affecting blood pressure variability: lessons learned from two systematic reviews of randomized controlled trials.影响血压变异性的因素:从两项随机对照试验的系统评价中获得的经验教训。
噻嗪类利尿剂单药治疗原发性高血压的降压疗效。
Cochrane Database Syst Rev. 2014 May 29;2014(5):CD003824. doi: 10.1002/14651858.CD003824.pub2.
4
Antihypertensive medications, bone mineral density, and fractures: a review of old cardiac drugs that provides new insights into osteoporosis.抗高血压药物、骨密度与骨折:对旧有心脏药物的综述为骨质疏松症提供新见解
Endocrine. 2014 Aug;46(3):397-405. doi: 10.1007/s12020-014-0167-4. Epub 2014 Feb 7.
5
Effects of eurythmy therapy in the treatment of essential arterial hypertension: a pilot study.韵律治疗对原发性高血压的治疗效果:一项初步研究。
Glob Adv Health Med. 2013 Jan;2(1):24-30. doi: 10.7453/gahmj.2013.2.1.006.
6
Blood pressure lowering efficacy of potassium-sparing diuretics (that block the epithelial sodium channel) for primary hypertension.保钾利尿剂(阻断上皮钠通道)对原发性高血压的降压疗效。
Cochrane Database Syst Rev. 2012 Nov 14;11(11):CD008167. doi: 10.1002/14651858.CD008167.pub3.
7
Augmented antihypertensive effect of a fixed combination formula of candesartan and hydrochlorothiazide combined with furosemide in a patient on peritoneal dialysis.坎地沙坦和氢氯噻嗪固定复方联合呋塞米在腹膜透析患者中增强降压作用。
Clin Exp Nephrol. 2011 Feb;15(1):175-8. doi: 10.1007/s10157-010-0355-3. Epub 2010 Oct 20.
PLoS One. 2009 May 22;4(5):e5673. doi: 10.1371/journal.pone.0005673.
4
Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension.血管紧张素转换酶(ACE)抑制剂对原发性高血压的降压疗效。
Cochrane Database Syst Rev. 2008 Oct 8;2008(4):CD003823. doi: 10.1002/14651858.CD003823.pub2.
5
Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension.血管紧张素受体阻滞剂对原发性高血压的降压疗效。
Cochrane Database Syst Rev. 2008 Oct 8;2008(4):CD003822. doi: 10.1002/14651858.CD003822.pub2.
6
Losartan with hydrochlorothiazide in the treatment of hypertension.氯沙坦与氢氯噻嗪联合治疗高血压。
J Hypertens Suppl. 1995 Jul;13(1):S43-7.
7
A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension.厄贝沙坦/氢氯噻嗪联合治疗与厄贝沙坦及氢氯噻嗪单药治疗中度高血压的疗效及安全性比较。
J Hum Hypertens. 2008 Apr;22(4):266-74. doi: 10.1038/sj.jhh.1002293. Epub 2007 Oct 11.
8
Antihypertensive efficacy and safety of fixed-dose combination therapy with losartan plus hydrochlorothiazide in Japanese patients with essential hypertension.氯沙坦加氢氯噻嗪固定剂量联合疗法对日本原发性高血压患者的降压疗效及安全性
Hypertens Res. 2007 Aug;30(8):729-39. doi: 10.1291/hypres.30.729.
9
Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients.雷米普利与坎地沙坦联合治疗对高血压患者心血管和代谢的附加有益作用。
Eur Heart J. 2007 Jun;28(12):1440-7. doi: 10.1093/eurheartj/ehm101. Epub 2007 May 5.
10
Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults.缬沙坦/氢氯噻嗪剂量高达320/25毫克的联合治疗与单药治疗的比较:一项针对高血压成人的双盲、安慰剂对照研究,随后进行长期联合治疗。
Clin Ther. 2007 Jan;29(1):61-73. doi: 10.1016/j.clinthera.2007.01.007.